Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 10/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Threonine SCHEMBL1965719 | 0.90 | DPP8 (0.31) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL1965723 | 0.89 | DPP4 (0.33) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL26134964 | 0.86 | DPP4 (0.37) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5161688 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3930248 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL122272 | 0.84 | SLC7A5 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL1537207 | 0.84 | SLC7A5 (0.44) | DPP4DPP8DPP9DPP7 | |
| Valine SCHEMBL17582481 | 0.84 | SLC7A5 (0.37) | — | |
| SCHEMBL8712673 | 0.84 | SLC7A5 (0.37) | DPP4 | |
| SCHEMBL1537395 | 0.83 | ALOX15 (0.43) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150752-A1 | METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240141330-A1 | METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-02 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| WO-2021151891-A1 | NOVEL PHYTOENE DESATURASE VARIANTS TO PRODUCE NEUROSPORENE AND/OR ZETA-CAROTENE | DEINOVE (FR) | 2021-08-05 | — | — | WO | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3737420-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2019136487-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-8323961-B2 | HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1675613-B1 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV | US GOV HEALTH & HUMAN SERV (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20100111998-A1 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN | 2010-05-06 | — | — | US | disclosed |
| US-7666427-B2 | HIV vaccines based on Env of multiple clades of HIV | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-02-23 | — | — | US | disclosed |
| US-20080286306-A1 | HIV vaccines based on Env of multiple clades of HIV | GENVEC, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20060275897-A1 | HIV vaccines based on Env of multiple clades of HIV | DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2006-12-07 | — | — | US | disclosed |
| EP-1675613-A2 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005034992-A2 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | DPP4 3149/4885DPP8 2394/4885DPP9 2531/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | DPP4 3149/4885DPP8 2394/4885DPP9 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.